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Abstract: There are few case reports documenting a new onset of demyelinating processes in patients 
receiving anti-tumour necrosis factor alpha therapy (anti-TNF alpha) for chronic inflammatory arthropathies. 
Whether anti-TNF alpha therapy induces new onset demyelination or just exacerbates pre-existing latent 
multiple sclerosis is not fully understood. We are reporting a 51-year-old woman without a prior history of 
multiple sclerosis, who developed demyelinating brain lesions three months after starting Etanercept. Her 
symptoms partially resolved on cessation of the drug. Our case was unusual compared to some previous 
case reports, as the patient’s age at presentation was beyond that for idiopathic multiple sclerosis. This may 
strengthen the hypothesis of a causal relationship between new onset demyelination and Etanercept; 
however, exacerbation of pre-existing demyelinating process by Etanercept in this patient still cannot be 
totally excluded. We recommend doing magnetic resonance imaging (MRI) of the brain before starting 
patients on anti-TNF alpha therapy to exclude latent demyelination.  In addition, new onset demyelination 
following anti-TNF alpha therapy should be reported and studied thoroughly as this may yield a significant 
advancement in our understanding of the pathogenesis of multiple sclerosis. Long-term follow-up of these 
cases is also important to determine the long-term prognosis and the rate of relapse of demyelinating process 
in this group of patients. 
 
Introduction 
Many rheumatic diseases including Rheumatoid 
arthritis (RA), Psoriatic arthritis (PsA) and 
Ankylosing spondylitis (AS) are autoimmune 
conditions, characterized by dysregulation and 
chronic activation of T-cell responses [1,2]. The 
ultimate outcome is overproduction of pro-
inflammatory cytokines, including tumor necrosis 
factor (TNF) alpha and interleukin 1, which have 
been postulated to mediate the joint destruction 
seen in RA [3,4]. Of note, B-cells seem also to 
play an important role in the pathogenesis of these 
diseases. They can act as antigen-presenting cells 
(APC) to T-cells and activate them, which in turn 
result in secretion of pro-inflammatory cytokines 
including TNF alpha [5]. Biological agents such as 
anti-tumor necrosis factor alpha (Anti-TNF alpha) 
have been approved for the treatment of certain 
diseases like inflammatory arthropathies, 
Psoariasis, and Crohn’s disease. In fact, these 
agents have revolutionized the treatment of these 
diseases, with demonstrated efficacy and safety 
[4,6]. However, several potential risks such as 
predisposition to some infections (especially 
tuberculosis), heart failure or development of 
lymphomas have been uncovered in post-
marketing reports. In addition, rare cases of new 
onset or exacerbations of central nervous system 
demyelination have been reported in the literature 
[7]. Etanercept is a fully human, soluble, TNF 
alpha receptor-IgG1 fusion protein that binds to 
both soluble and membrane bound TNF alpha, 
thereby inhibiting its interaction with cell surface 
receptors and preventing TNF mediated cellular 
responses. Etanercept has been approved by the 
Federal Drug Administration (FDA) for the 
treatment of subjects with moderately to severely 
active RA, Polyarticular juvenile RA (JRA), AS, 
PsA and psoriasis [8]. 
We report a case of new onset demyelinating 
disease that developed in a temporal association 
with the use of Etanercept in a patient whose age 
is beyond that for idiopathic multiple sclerosis. 
 
Case report 
A 51-year old woman with a 2-year history of 
rheumatoid arthritis presented with three weeks 
history of vertigo and vomiting. Her symptoms 
worsened progressively and she became 
unsteady on walking. She also felt episodes of 
tingling and numbness on the right side of the 
face. There was no prior history of neurological 
disease and no family history of multiple sclerosis. 
She was maintained on Methotrexate 20 mg 
weekly for the arthritis, however due to inadequate 
response, subcutaneous Etanercept 50 mg weekly 
was begun three months prior to her admission 
with marked improvement in her joint symptoms. 
She had received the last dose of Etanercept four 
days prior to hospital admission. Past medical 
history was also significant for 1-year history of 
diabetes on Metformin, and hypercholesterolemia 
on Simvastatin 10 mg. The physical examination 
revealed a horizontal nystagmus with fast 
component towards left side and broad-based, 
ataxic gait with tendency to fall to the left side. 
Rest of examination was unremarkable and there 
were no signs of active joint disease. 
Complete blood count, urea, electrolytes, and 
blood sugar were normal and Electrocardiography 
revealed occasional ventricular ectopic beats. 
Autoimmune tests including ANA, Anti-ds DNA 
and Anti-CCP were negative. Rheumatoid factor 
also was negative at admission.    
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MRI of the brain (Figure 1) revealed multiple 
rounded foci with iso-intense T1 and hyper-intense 
FLAIR and T2 signals involving the left side of the 
medulla, the right middle cerebral peduncle, the 
body of the corpus callosum and the sub-cortical 
white matter of both cerebral hemispheres, which 
were suggestive of demyelinating foci. The patient 
refused lumbar puncture. 
 
 
Figure 1: MRI brain showing demyelinating lesions. 
 
Etanercept was discontinued immediately. Three 
days later she felt better, with reduction in intensity 
of vertigo and disappearance of nystagmus, 
however her gait remained ataxic. 
Intravenous methylprednisolone pulse therapy 
was then started and three days later, she made a 
good recovery and was able to walk unsupported. 
She was discharged on oral prednisolone 60 mg 
daily to be tapered gradually and then maintained 
on Methylprednisolone 4 mg daily. Three months 
later, she presented with new onset ataxia, double 
vision and vertigo. Neurological examination 
revealed ataxic gait, nystagmus with fast 
component to left side. Repeated MRI of the brain 
(Figure 2) revealed a newly developed rounded, 
about 1 cm in size, demyelinating lesion in the 
right posterior pariental area, with scattered small 
demyelinating lesions. The patient requested 
discharge to seek a second opinion abroad. 
 
Discussion 
Anti-TNF alpha therapy was initially considered 
for the treatment of multiple sclerosis based on 
studies of experimental autoimmune 
encephalomyelitis (EAE), which is considered a 
model for human multiple sclerosis [9-11]. 
Blocking TNF alpha with antibodies decreased 
EAE severity in rodents [12]. In humans high 
levels of TNF alpha have been found in multiple 
sclerosis plaques and cerebrospinal fluid [13]. But 
despite these findings, anti-TNF alpha treatment 
for multiple sclerosis worsens the disease. In a 
trial of anti-TNF alpha therapy using Lenercept for 
patients with multiple sclerosis, treated patients 
had significantly more exacerbations than 
placebo-treated patients [14]. In addition, 
treatment with anti-TNF alpha antibody in two 
patients with rapidly progressing multiple sclerosis 
led to a transient increase in gadolinium-
enhancing lesions and no improvement in disease 
severity [15]. Based on these studies, anti-TNF 
alpha agents were abandoned as candidate drugs 
for the treatment of multiple sclerosis [9].  
 
 
Figure 2: MRI brain 3 months later 
 
Nonetheless the recent approval of these agents 
for the treatment of certain chronic inflammatory 
arthropathies, Crohn’s disease and Psoriasis, has 
had a major impact on the outcome of these 
diseases. These agents have led to significant 
improvement in most patients with inflammatory 
arthropathies, which were resistant to 
conventional forms of treatment. In fact, these 
agents revolutionized the treatment of chronic 
inflammatory arthropathies. However, since the 
approval of anti-TNF alpha agents, rare cases of 
new onset or exacerbations of demyelinating 
diseases have been reported. This includes 
multiple sclerosis-like disease, optic neuritis, 
myelitis or chronic inflammatory demyelinating 
polyneuropathy [7]. Central nervous system 
demyelination following anti TNF alpha therapy 
has been reported with different agents like 
Infliximab, Etanercept and Adalimumab that were 
indicated for diseases like Crohn’s disease, 
Inflammatory arthropathies and Psoriasis [7,16-
19]. 
In 2001, Mohan et al [9] queried the Adverse 
Events Reporting system of the Food and Drug 
Administration for neurological events suggestive 
of demyelination following anti-TNF alpha therapy. 
Nineteen patients with demyelinating-like 
neurological events were identified, 17 who had 
been receiving Etanercept and two who had been 
receiving infliximab. The most common presenting 
clinical symptoms were parasthesias (13 patients),    
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optic neuritis (eight patients), confusion (five 
patients), gait disturbance, apraxia, and facial 
palsy and Guillain-Barre syndrome. The average 
time between the beginning of therapy and the 
onset of symptoms was five months. Cessation of 
anti-TNF alpha therapy resulted in complete or 
partial improvement of symptoms in all patients. 
One patient noted return of symptoms when 
therapy was tried again. The duration of therapy 
before development of neurological symptoms 
ranged from one week to 15 months, with a mean 
duration of five months. 
 
Table 1  Characteristics of some cases reported in 
literature 
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Al saieg
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Ruiz-
Jimeno
25  06 47  F  6  I  PsA N  Y 
Sukal
16 06  18  F  12  E  Pe  N  N 
Mejico
17 04  50  F 1 I  C N  N 
Tanno
26 06  56  M  1 I RA  N  N 
Ibrahim 
(current 
case) 
06 51  F  3  E  RA  N  Y 
E: Etanercept, I: Infliximab, RA: rheumatoid arthritis, 
JRA: juvenile rheumatoid arthritis, PsA: psoriatic 
arthritis, Pe: psoriatic erythroderma, C: Crohn’s disease  
N: No, Y: Yes  
 
The overall number of individuals with new onset 
demyelinating events on anti-TNF alpha therapy 
appears to be small, but these episodes can be 
clinically silent, making it difficult to assess the 
actual number of affected individuals [20]. In 
addition the condition may be under-reported due 
to the unawareness and the non-specific 
presentation. Parasthesia, which is the most 
common symptom [9] may be easily attributed to 
the rheumatologic disease itself or associated 
illness. In a recent meta-analysis of 22 trials done 
on rheumatoid arthritis, psoriatic arthritis, and 
ankylosing spondylitis patients, Fleischmann et al 
[21] assessed the long-term safety of Etanercept 
in elderly subjects with rheumatic diseases. Out of 
the 4322 subjects studied, only eight cases of 
demyelinating disorders were diagnosed in 
subjects aged less than 65 and no cases of 
demyelinating disease in subjects aged ≥ 65. In 
the recent German Etanercept registry for the 
treatment of juvenile idiopathic arthritis, out of the 
324 subjects studied, only one had central 
nervous system demyelination [22].  
 
 
CONCLUSION 
Our patient did not have past history of multiple 
sclerosis. In addition, her age at presentation was 
beyond that for multiple sclerosis. Her symptoms 
partially resolved on cessation of Etanercept. This 
may suggest a causal relationship between new 
onset demyelination and Etanercept. 
Nevertheless, exacerbation of pre-existing occult 
(asymptomatic) demyelinating disease can’t be 
totally excluded as the cause of this patient’s 
clinical presentation. Therefore, we recommend 
doing MRI of the brain before starting patients on 
anti-TNF alpha therapy. This will definitely 
determine whether a demyelination process is a 
new onset, anti-TNF alpha related or merely due 
to latent multiple sclerosis exacerbation. In 
addition, we recommend that all cases of new 
onset demyelination should be reported and 
studied thoroughly as this will not only help to 
avoid a serious adverse event but may also yield a 
significant advancement in our understanding of 
the pathogenesis of multiple sclerosis. 
Furthermore, follow-up of these cases should be 
encouraged in order to determine the long-term 
prognosis and relapse rate of demyelinating 
process in these patients. 
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